Immuneering Corp
NASDAQ:IMRX
Immuneering Corp
Total Current Liabilities
Immuneering Corp
Total Current Liabilities Peer Comparison
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
I
|
Immuneering Corp
NASDAQ:IMRX
|
Total Current Liabilities
$7.8m
|
CAGR 3-Years
51%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$41.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
24%
|
CAGR 10-Years
21%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$13B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$19.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$3.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
19%
|
CAGR 10-Years
28%
|
See Also
What is Immuneering Corp's Total Current Liabilities?
Total Current Liabilities
7.8m
USD
Based on the financial report for Dec 31, 2023, Immuneering Corp's Total Current Liabilities amounts to 7.8m USD.
What is Immuneering Corp's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 3Y
51%
Over the last year, the Total Current Liabilities growth was -3%. The average annual Total Current Liabilities growth rates for Immuneering Corp have been 51% over the past three years .